Ketohexokinase inhibition
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Ketohexokinase inhibition
Ketohexokinase inhibition is a phase 2 stage product being developed by Pfizer for NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT05463575. Target conditions include NAFLD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05463575 | Phase 2 | Completed |
Competing Products
15 competing products in NAFLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| Saroglitazar | Zydus Lifesciences | Approved | 85 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Placebo + RO5093151 | Roche | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination | Pfizer | Phase 2 | 51 |
| BMS-986036 | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-PNP + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Legalon® 140 mg | Viatris | Pre-clinical | 20 |
| Elobixibat + Placebo oral tablet | Ipsen | Phase 2 | 49 |
| Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg | Ionis Pharmaceuticals | Phase 2 | 49 |
| EDP 305 + Placebo | Enanta Pharmaceuticals | Phase 1 | 25 |